Document is current
Any future updates will be listed below
-
Authors
Vorobyev, Artem
Gupta, Yask
Sezin, Tanya
Koga, Hiroshi https://orcid.org/0000-0001-7027-032X
Bartsch, Yannic C.
Belheouane, Meriem
Künzel, Sven
Sina, Christian
Schilf, Paul
Körber-Ahrens, Heiko
Beltsiou, Foteini https://orcid.org/0000-0001-8653-4908
Lara Ernst, Anna https://orcid.org/0000-0002-5884-9870
Khil’chenko, Stanislav https://orcid.org/0000-0003-4740-5892
Al-Aasam, Hassanin https://orcid.org/0000-0002-9331-648X
Manz, Rudolf A. https://orcid.org/0000-0003-1263-7693
Diehl, Sandra
Steinhaus, Moritz
Jascholt, Joanna
Kouki, Phillip
Boehncke, Wolf-Henning
Mayadas, Tanya N.
Zillikens, Detlef https://orcid.org/0000-0002-5668-307X
Sadik, Christian D. https://orcid.org/0000-0001-6701-048X
Nishi, Hiroshi
Ehlers, Marc https://orcid.org/0000-0002-5383-8603
Möller, Steffen https://orcid.org/0000-0002-7187-4683
Bieber, Katja https://orcid.org/0000-0002-3855-6683
Baines, John F.
Ibrahim, Saleh M.
Ludwig, Ralf J. https://orcid.org/0000-0002-1394-1737
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 306, EXC 2167, DGRK 1473, GRK 1727)
- License Information
-
More Information
Article History
Received: 21 February 2019
Accepted: 13 August 2019
First Online: 10 September 2019
Competing interests
: R.J.L. has received research funding from Miltenyi Biotec, Biogen, Biotest, Almirall, True North Therapeutics, UCB Pharma, ArgenX, TxCell, Topadur, Incyte and Admirx and fees for consulting or speaking from ArgenX, Immunogenetics, Novartis and Lilly. All other authors declare no competing interests.
